Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Rocketvax Collaborates with NIH for Clinical Trial of RVX-sCPD9 Candidate | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Rocketvax Collaborates with NIH for Clinical Trial of RVX-sCPD9 Candidate

The partnership will advance the development of a next-generation SARS-CoV-2 vaccine platform into the clinical stage.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Biotech company Rocketvax AG’s RVX-sCPD9 candidate for the prevention of SARS-CoV-2 has been selected to be part of Project NextGen, an initiative by the U.S. Department of Health and Human Services aimed at advancing a pipeline of new, innovative vaccines providing broader and more durable protection against COVID-19.
 
As part of Project NextGen, the National Institute of Allergy and Infectious Diseases (NIAID), which is a part of the National Institutes of Health, will support a Phase 1 clinical study with Rocketvax’s RVX-sCPD9 vaccine, subject to regulatory approval. NIAID will sponsor the study.
 
“We are extremely pleased with the support from the US NIH/NIAID and the clinical potential of our RVX-sCPD9 live-attenuated vaccine. This vaccine is based on our proprietary reverse genetics engineering platform technology (Viruflex) and NIH will provide non-dilutive financial support for the advancement of our lead vaccine candidate,” said Vladimir Cmiljanović, Ph.D., Rocketvax’s CEO. “Partnership with the NIH/NIAID will advance the development of a next-generation SARS-CoV-2 vaccine platform into the clinical stage.”
 
Rocketvax’s lead candidate uses convenient nasal administration and, in animal studies, demonstrated high efficacy across viral strains, long-lasting protection, and the ability to prevent virus transmission.
 
The company believes that this clinical study will reinforce its efforts in extending the platform beyond SARS-CoV-2, focusing on infectious diseases, pandemic readiness, and cancer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics